NR3C1 and Familial prostate cancer: In prostate cancer, the glucocorticoid receptor (GR) is a prime suspect for acquired therapy resistance, as resistance to the antiandrogen enzalutamide (Enz) can occur through bypass of androgen receptor (AR) blockade by the glucocorticoid receptor (GR)[70].